Samjin Pharmaceutical has signed a strategic memorandum of understanding (MOU) with Ewha Seoul Hospital for research on central nervous system (CNS) disease treatments.
The company announced Wednesday that the two institutions will conduct joint research to develop treatments for various CNS disorders including migraines. The partnership aims to establish an organic cooperation system through the exchange of expertise and business coordination.
According to Samjin Pharmaceutical, the institutions have established a role-sharing framework based on each organization's core competencies. Samjin Pharmaceutical will handle early-stage drug development research, including antibody discovery and engineering, candidate optimization, and in vitro and in vivo preclinical evaluation. Ewha Seoul Hospital will provide support for understanding diseases and pathophysiology, as well as advisory services and expert opinions on mechanism validation from a clinical efficacy perspective.
Professor Song Tae-jin, who was appointed as director of Ewha Womans University Medical Research Institute last month, will serve as a clinical advisor and validate disease mechanisms in this joint research. Song is a renowned specialist in the migraine field.
Samjin Pharmaceutical and Ewha Seoul Hospital also plan to actively explore participation in joint research utilizing government-funded projects and industry-academia-research collaboration programs. Details regarding intellectual property rights, scope of roles, cost sharing, and commercialization structures arising from the joint research will be finalized through separate agreements and contracts.
"We have high expectations for collaborating with Ewha Seoul Hospital, which possesses excellent clinical expertise in CNS disorders including migraines," said Lee Su-min, head of Samjin Pharmaceutical's Research Center. "The combination of Samjin Pharmaceutical's antibody research capabilities and Ewha Seoul Hospital's clinical research infrastructure will serve as a catalyst for accelerating innovative treatment development."
